Biotechnology Companies Ramp up Funding as Deadly Diseases Come Into the Spotlight
News commentary on marketwatch.com about Algernon Pharmaceuticals.
The article addresses how biotechnology is rapidly and continually evolving each year with new innovative therapies and drugs, and how the market valued at USD 399.4 Billion in 2017 is projected to witness a robust CAGR of 9.9% from 2018 to 2024.
This news commentary talks about Idiopathic Pulmonary Fibrosis (IPF) studies and how a successful IPF in vivo study for NP-251 would mean that Algernon could begin planning an additional phase II study for its fourth major global disease.
A chest radiograph of a patient with IPF. Source: IPFeditor, on Wikipedia